Celltrion, Inc.
068270
Kedudukan dalam Saham
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Harga Saham
$146.63
Modal Pasaran
$33.44B
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
23.60%
Negara
KR
Perdagangan Celltrion, Inc. (068270)
Kategori
Healthcare
Margin Operasi untuk Celltrion, Inc. (068270)
Margin Operasi pada October 2026 TTM: 31.56%
Menurut laporan kewangan dan harga saham terkini Celltrion, Inc., margin operasi semasa (TTM) ialah 31.56%. Pada akhir 2024, margin operasi syarikat ialah 13.83%.
Sejarah Margin Operasi untuk Celltrion, Inc. dari 2007 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | 31.56% | 12.43% |
| 2025 | 28.07% | 102.96% |
| 2024 | 13.83% | -53.79% |
| 2023 | 29.93% | 5.61% |
| 2022 | 28.34% | -27.89% |
| 2021 | 39.30% | 1.13% |
| 2020 | 38.86% | 14.94% |
| 2019 | 33.81% | 2.77% |
| 2018 | 32.90% | -37.50% |
| 2017 | 52.64% | 41.35% |
| 2016 | 37.24% | -13.21% |
| 2015 | 42.91% | 0.33% |
| 2014 | 42.77% | -3.10% |
| 2013 | 44.14% | -20.91% |
| 2012 | 55.81% | -13.15% |
| 2011 | 64.26% | 9.06% |
| 2010 | 58.92% | 19.51% |
| 2009 | 49.30% | 34.08% |
| 2008 | 36.77% | 1,237.09% |
| 2007 | 2.75% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 28.81% | -99.09% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.